{
    "Trade/Device Name(s)": [
        "Tina-Quant D-Dimer Test System",
        "Tina-Quant\u00ae D-Dimer Test System"
    ],
    "Submitter Information": "Roche Diagnostics Corporation",
    "510(k) Number": "K062203",
    "Predicate Device Reference 510(k) Number(s)": [
        "K030740",
        "K040822"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GHH"
    ],
    "Summary Letter Date": "July 31, 2006",
    "Summary Letter Received Date": "August 1, 2006",
    "Submission Date": "November 3, 2006",
    "Regulation Number(s)": [
        "21 CFR 864.7320"
    ],
    "Regulation Name(s)": [
        "Fibrinogen/Fibrin Degradation Products Assay"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "D-Dimer",
        "X-oligomers",
        "Fibrin degradation products"
    ],
    "Specimen Type(s)": [
        "Citrated plasma",
        "Li-Heparin plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Roche Hitachi family of analyzers",
        "COBAS Integra family of analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoturbidimetric assay"
    ],
    "Methodologies": [
        "Particle-enhanced immunoturbidimetric assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "System",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Tina-Quant D-Dimer Test System on Roche Hitachi and COBAS Integra analyzers for quantitative determination of fibrin degradation products to aid in exclusion of DVT and PE",
    "Indications for Use Summary": "For quantitative determination of fibrin degradation products including D-Dimer and X-oligomers; a normal result in conjunction with non-high clinical probability assessment excludes deep vein thrombosis and pulmonary embolism with high sensitivity",
    "fda_folder": "Hematology"
}